Mannkind (MNKD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$393.6M

Revenue (quarter)

$109.4M

Revenue growth (year over year)

+42.92%

Gross profit (trailing twelve months)

$296.7M

Gross margin

75.39%

Net income (trailing twelve months)

−$43.6M

Net income (quarter)

−$19.0M

Net income growth (year over year)

−2949.10%

Net margin

−11.08%

Return on equity

—

EPS (trailing twelve months)

−$0.15

Book value per share

−$0.22

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

109.18%

Payout ratio

—

Dividend yield

—

Company profile

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

• Is Mannkind (MNKD) profitable?

  No. Mannkind reported a net loss of $43.6M over the trailing twelve months.

• How much revenue does Mannkind (MNKD) make?

  Mannkind generated $393.6M in revenue over the trailing twelve months, up 42.92% year over year.

• How do I buy stock in Mannkind (MNKD)?

  MNKD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.